Kataoka Kozo, Aoyama Ikuo, Mizusawa Junki, Eba Junko, Minashi Keiko, Yano Tomonori, Tanaka Masaki, Hanaoka Noboru, Katayama Hiroshi, Takizawa Kohei, Fukuda Haruhiko, Muto Manabu
JCOG Data Center/Operations Office, Center for Research Administration and Support, National Cancer Center, Tokyo.
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto.
Jpn J Clin Oncol. 2015 Apr;45(4):385-9. doi: 10.1093/jjco/hyv006. Epub 2015 Jan 27.
A randomized Phase II/III trial commenced in May 2014. Endoscopic balloon dilation with steroid injection is the current standard treatment for patients with refractory anastomotic stricture after esophagectomy. The purpose of this study is to confirm the superiority of radial incision and cutting with steroid injection in terms of both restricture-free survival and number of dilations within 24 weeks compared with endoscopic balloon dilation with steroid injection for these patients. A total of 130 patients will be accrued from 30 Japanese institutions over 3 years. The primary endpoint in the Phase II part is proportion of Grade 3/4 intraoperative hemorrhages, post-operative esophageal perforations, esophageal hemorrhages, pneumothorax, lung or mediastinum infections or other unexpected adverse events. Co-primary endpoints in the Phase III part are restricture-free survival and number of dilations within 24 weeks after treatment. Secondary endpoints are proportion of patients with anastomotic diameter >10 mm at 8 weeks after treatment, proportion of adverse events, proportion of patients experiencing improvement of dysphagia score at 2, 4, 8 and 24 weeks after treatment and proportion of patients with dysphagia score ≤1 at 24 weeks after treatment. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000014017 [http://www.umin.ac.jp/ctr/index.htm].
一项随机II/III期试验于2014年5月开始。内镜下球囊扩张联合类固醇注射是食管癌切除术后难治性吻合口狭窄患者的当前标准治疗方法。本研究的目的是证实与内镜下球囊扩张联合类固醇注射相比,放射状切开加类固醇注射在无狭窄生存期和24周内扩张次数方面的优越性。将在3年内从30家日本机构招募总共130名患者。II期部分的主要终点是3/4级术中出血、术后食管穿孔、食管出血、气胸、肺部或纵隔感染或其他意外不良事件的比例。III期部分的共同主要终点是治疗后24周内的无狭窄生存期和扩张次数。次要终点是治疗后8周吻合口直径>10 mm的患者比例、不良事件比例、治疗后2、4、8和24周吞咽困难评分改善的患者比例以及治疗后24周吞咽困难评分≤1的患者比例。该试验已在UMIN临床试验注册中心注册为UMIN000014017 [http://www.umin.ac.jp/ctr/index.htm]。